Jacob Travers

JACOB TRAVERS represents issuers, underwriters and major shareholders in a variety of SEC-registered and exempt transactions, both U.S. and cross-border, including initial public offerings, SPAC and de-SPAC transactions, common and preferred equity offerings, debt offerings and public M&A transactions. He also advises clients on corporate governance matters and ongoing disclosure obligations, including compliance with the Exchange Act disclosure requirements, New York Stock Exchange, and Nasdaq corporate governance rules

• A German biopharmaceutical company in a cash capital increase via an accelerated bookbuilding, raising approximately €102.7 million.
  
• A Norwegian battery technology company in its first SEC-registered follow-on offering of ordinary shares, raising US$264.5 million.

• A special purpose acquisition company in its US$863 million initial public offering and its $500 million business combination with a medical technology company focused on weight management.
  
• A special purpose acquisition company in its US$345 million initial public offering and its $8 billion business combination with an Indian renewable power company, as well as its $855 million accompanying PIPE transaction.

• The initial purchasers in connection with the debut issuance of €500 million and US$510 million of Green Senior Secured Notes due 2030 by a global clean energy power producer portfolio company of a global private equity firm, as well as a subsequent issuance of €675 million of Senior Secured Notes due 2031.
  
• A Nordic operator of ferry services in connection with its issuance of US$350 million and €315 million of Senior Secured Notes due 2025 and its related tender offer for existing notes.

• A multinational telecommunications company in connection with its approximately US$6.2 billion acquisition of a global tower infrastructure company.
  
• A leading global paper and packaging company in connection with its approximately US$9.9 billion acquisition of a UK-listed packaging company.
  
• The special committee of a UK-listed gene therapy company in connection with its take-private acquisition by a life sciences investment company.
  
• A Finnish food delivery company in connection with its approximately US$8 billion acquisition by a leading U.S. food delivery platform.